Marina Chiara Garassino to Prospective Studies
This is a "connection" page, showing publications Marina Chiara Garassino has written about Prospective Studies.
Connection Strength
0.349
-
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open. 2021 02; 6(1):100034.
Score: 0.106
-
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 2020 05; 5(3):e000748.
Score: 0.101
-
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
Score: 0.031
-
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
Score: 0.031
-
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 01; 12(1):90-107.
Score: 0.028
-
Cognitive impairment and chemotherapy: a brief overview. Crit Rev Oncol Hematol. 2017 Oct; 118:7-14.
Score: 0.021
-
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. 2015 Oct; 26(10):2079-84.
Score: 0.018
-
A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer. 2012 Mar; 20(3):475-81.
Score: 0.013